PRAXIS ASA EC 81 MG DAILY LOW DOSE TABLET (DELAYED-RELEASE)

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

ACETYLSALICYLIC ACID

Dostopno od:

PHARMASCIENCE INC

Koda artikla:

B01AC06

INN (mednarodno ime):

ACETYLSALICYLIC ACID

Odmerek:

81MG

Farmacevtska oblika:

TABLET (DELAYED-RELEASE)

Sestava:

ACETYLSALICYLIC ACID 81MG

Pot uporabe:

ORAL

Enote v paketu:

500/1000

Tip zastaranja:

OTC

Terapevtsko območje:

SALICYLATES

Povzetek izdelek:

Active ingredient group (AIG) number: 0101169013; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2009-08-07

Lastnosti izdelka

PRODUCT MONOGRAPH
PRAXIS ASA EC 81 MG DAILY LOW DOSE
Acetylsalicylic
Acid Delayed-release Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
March 30, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 262153
_Product Monograph - PRAXIS ASA EC 81 mg Daily Low Dose _
_ _
_ _
_ _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................3
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE
REACTIONS..............................................................................................6
DRUG INTERACTIONS
..............................................................................................7
DOSAGE AND ADMINISTRATION
...........................................................................9
OVERDOSAGE
.........................................................................................................
10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
11
STORAGE AND STABILITY
....................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
................................................................... 12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 13
PART II : SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
.....................................................................
14
CLINICAL TRIALS
..........................................................